Remi Barbier, the Company’s founder, has served as President, Chief Executive Officer and Chairman of the Board of Directors since the Company’s inception in 1998. Prior to that time, Mr. Barbier helped in the growth or founding of Exelixis Inc., a publicly-traded drug development company, ArQule, Inc., a drug development company acquired by Merck & Co., and EnzyMed, Inc., a chemistry company acquired by Albany Molecular Research, Inc. Mr. Barbier is a trustee emeritus of the Carnegie Institute of Washington, the Santa Fe Institute, the Advisory Board of the University of California Institute for Quantitative Biosciences and a life science incubator at the University of Arkansas for Medical Sciences.

James W. Kupiec, M.D. joined the Company in January 2021 as Chief Clinical Development Officer and has served as our Chief Medical Officer since December 2022. Dr. Kupiec joined the Company after three decades of drug development experience at Pfizer, Sanofi and Ciba-Geigy. Dr. Kupiec previously served as VP, Global Clinical Leader for Parkinson’s Disease and Clinical Head of the Neuroscience Research Unit for Pfizer, Inc., in Cambridge, MA. He joined Pfizer in 2000 after seven years with Sanofi, and two years with Ciba-Geigy Pharmaceuticals. During his 17-year career at Pfizer, Dr. Kupiec had extensive governance, business development, alliance and leadership responsibilities. Dr. Kupiec earned his BS with Honors in Biochemistry at Stony Brook University and his MD from the Albert Einstein College of Medicine. He completed his residency training at the Strong Memorial Hospital, University of Rochester School of Medicine, and is certified by the American Board of Internal Medicine. He served as an investigator on many clinical trials before joining the pharmaceutical industry.

Chris Cook joined SAVA as Senior Vice President and General Counsel in October 2022. He previously served as the Global Head of Litigation and Government Investigations for Alcon, a publicly traded medical device and pharmaceutical company, as well as the Vice President and division General Counsel for Walmart Central America in San Jose, Costa Rica. Chris also spent seventeen years at Jones Day, where he was a litigation partner in the firm's Washington, DC and Chicago offices. Chris served as an Assistant United States Attorney in Chicago and graduated from Harvard Law School.

Eric Schoen has served as SAVA’s Chief Financial Officer since 2018. Prior to joining the Company, Mr. Schoen served as Vice President, Senior Vice President, Finance and Chief Accounting Officer of Aspira Women’s Health Inc. (formerly Vermillion, Inc.), a publicly-held women’s health company, from 2011 to 2017. Mr. Schoen also began his career and spent nine years with PricewaterhouseCoopers in the audit and assurance, transaction services and global capital markets practices.

Lindsay H. Burns, PhD has been the lead scientist on Cassava Sciences’ Alzheimer’s disease program since she and Dr. Hoau-Yan Wang discovered simufilam's novel target. Dr. Burns has led the program through medicinal chemistry, lead profiling and IND-enabling studies to its current stage of clinical trials in Alzheimer’s disease patients. Trained in neuropsychology at the University of Cambridge and Harvard College, Dr. Burns has a broad background in neuroscience and neurodegenerative disease that spans functional in vitro assays, preclinical models of disease and cognitive/behavioral testing.

Mike Zamloot has 35 years of pharmaceutical industry experience with multinational firms and development stage biopharmaceutical companies. He has held his current position with Cassava Sciences since 2000, and has responsibility for all aspects of Pharmaceutical Development, Quality and Supply Chain Management. Mike holds a BS degree in Chemical Engineering with honors from the New Jersey Institute of Technology and is an inventor on more than 25 patents.

Ben Thornton has over 30 years experience in leading research and development teams in large pharma (Johnson & Johnson) and start up biotechnology companies (GeneMedicine, Apovia) translating basic science to the clinical setting. He has held his current position with Cassava Sciences since 2005. Ben holds a PhD in Molecular Biology from the University of Texas M.D. Anderson School of Biomedical Sciences and was a post-doctoral fellow at the Roche Institute of Molecular Biology. He is currently a Trustee of The Torrey Pines Institute for Molecular Sciences.

Mike Marsman, PharmD has worked with SAVA as an employee or consultant since 2004. He has over 35 years providing leadership for Regulatory Affairs and Quality Assurance with both multinational and development stage pharmaceutical companies, including Impax, Millennium, COR Therapeutics, Liposome Technology, and Syntex. Dr. Marsman achieved multiple FDA drug approvals prior to joining Cassava Sciences.